BiotechTubeBiotechTube
Home/Pipeline/CYMS101

CYMS101

Multiple Sclerosis

Pre-clinical / Limited ClinicalActive

Key Facts

Indication
Multiple Sclerosis
Phase
Pre-clinical / Limited Clinical
Status
Active
Company
FibroBiologics

About FibroBiologics

FibroBiologics is developing a novel class of biologic treatments based on fibroblasts, one of the most abundant cells in the human body. The company claims its fibroblast platform offers superior potency, easier sourcing, and lower manufacturing costs compared to stem cell therapies. With over 270 patents and an IND-cleared program for degenerative disc disease, FibroBiologics is positioning itself as a leader in next-generation regenerative medicine.

View full company profile

Therapeutic Areas

Degenerative Disc DiseaseMultiple SclerosisWound HealingPsoriasisOncologyDiabetesAnti-Aging / Immunosenescence

Other Multiple Sclerosis Drugs

DrugCompanyPhase
Zeposia (ozanimod)Bristol Myers SquibbCommercial
Copaxone (glatiramer acetate)Teva Pharmaceutical IndustriesCommercial
Multiple Sclerosis PortfolioBiogenCommercial
Kesimpta (ofatumumab)GenmabApproved
Glatiramer Acetate (Generic Copaxone)Dr. Reddy's LaboratoriesApproved
Glatiramer AcetateCiplaCommercial
Interferon β-1aBachemCommercial
KYV-101Kyverna TherapeuticsPhase 1/2
Azer-cel (PBCAR0191)Precision BioSciencesPhase 1/2